Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study - Banerjee, A; Lane, DA; Torp-Pedersen, C; Lip, GYH (Thromb Haemost, 2012)